Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 15:14:1150498.
doi: 10.3389/fendo.2023.1150498. eCollection 2023.

Precocious puberty in patients with Pompe disease

Meng-Ju Melody Tsai  1   2 , Mei-Huei Chen  1   3 , Yin-Hsiu Chien  1   4 , Yi-Ching Tung  1
Affiliations

Precocious puberty in patients with Pompe disease

Meng-Ju Melody Tsai et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: The life expectancy of Pompe disease patients has increased due to improved neonatal screening and enzyme replacement therapy. Nevertheless, the potential effect of frequent medical device exposure on pubertal development in these patients is not well understood, so further investigation is warranted.

Methods: In this cross-sectional study, we assessed the growth and puberty of nine Pompe disease patients. In addition, to determine the effects of frequent plastic medical device exposure in these patients, we measured urinary phthalate metabolites before and one day after enzyme replacement therapy.

Results: Five out of nine patients (55%) with Pompe disease on enzyme replacement therapy had precocious puberty. Patients with precocious puberty had significantly shorter predicted adult heights compared to those with normal puberty (p = 0.014). The levels of mono-2-ethylhexyl phthalate (MEHP) and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP) increased after enzyme replacement therapy, but the average levels of phthalate metabolites did not significantly differ between patients with normal and precocious puberty.

Conclusion: Pompe disease patients on enzyme replacement therapy tend to have precocious puberty, which may reduce their adult height. There are no significant differences in urinary phthalate metabolites between normal and precocious puberty patients. Regular follow-up of growth and puberty in Pompe disease patients is important to improve their health outcomes.

Keywords: Pompe disease; enzyme replacement therapy; mono-2-ethylhexyl phthalate; phthalate exposure; precocious puberty.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Kohler L, Puertollano R, Raben N. Pompe disease: from basic science to therapy. Neurotherapeutics (2018) 15(4):928–42. doi: 10.1007/s13311-018-0655-y - DOI - PMC - PubMed
    1. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. . A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr-Us (2006) 148(5):671–6. doi: 10.1016/j.jpeds.2005.11.033 - DOI - PubMed
    1. Ries M. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016). J Inherit Metab Dis (2017) 40(3):343–56. doi: 10.1007/s10545-017-0032-8 - DOI - PubMed
    1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet (2008) 372(9646):1342–53. doi: 10.1016/S0140-6736(08)61555-X - DOI - PubMed
    1. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. . Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics (2008) 122(1):e39–45. doi: 10.1542/peds.2007-2222 - DOI - PubMed